Search

Search Constraints

You searched for: Subject Neoadjuvant therapy -- Pathologic response -- Melanoma -- Immunotherapy

Search Results

1. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. (May 2021)